10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ELEVANCE HEALTH, INC. | |||
Ticker: ELV Fiscal Year: 2016 | |||
Consolidated Statements of Cash Flows | |||
Period Ending Dec 31, 2016 10-K (Filed: Feb 22, 2017) | |||
| (In Thousands, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | |
| Operating activities | |||
| Net income | $ 2,469,800 | 2,560,000 | 2,569,700 |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Net realized gains on financial instruments | (4,900) | (157,500) | (177,000) |
| Other-than-temporary impairment losses recognized in income | 115,400 | 83,400 | 49,000 |
| (Gain) loss on extinguishment of debt | 0 | (9,300) | 81,100 |
| Gain on disposal from discontinued operations | 0 | 0 | (3,200) |
| Loss (gain) on disposal of assets | 4,500 | 16,000 | (1,700) |
| Deferred income taxes | 126,900 | (65,900) | 30,700 |
| Amortization, net of accretion | 807,800 | 802,100 | 744,500 |
| Depreciation expense | 104,000 | 105,800 | 106,500 |
| Impairment of property and equipment | 44,800 | 1,800 | 7,900 |
| Share-based compensation | 164,600 | 148,200 | 168,900 |
| Excess tax benefits from share-based compensation | (53,500) | (95,800) | (46,400) |
| Changes in operating assets and liabilities: | |||
| Receivables, net | (1,380,500) | (42,900) | (1,899,700) |
| Other invested assets | (19,400) | 5,900 | (21,700) |
| Other assets | (127,700) | 33,800 | 405,500 |
| Policy liabilities | 321,700 | 193,000 | 1,240,600 |
| Unearned income | (173,600) | 33,900 | 255,100 |
| Accounts payable and accrued expenses | 116,600 | (219,300) | (14,400) |
| Other liabilities | 605,700 | 686,400 | (7,900) |
| Income taxes | 178,800 | 41,500 | (34,000) |
| Other, net | (96,500) | (5,100) | (84,200) |
| Net cash provided by operating activities | 3,204,500 | 4,116,000 | 3,369,300 |
| Investing activities | |||
| Purchases of fixed maturity securities | (10,157,700) | (9,792,000) | (9,613,400) |
| Proceeds from fixed maturity securities: | |||
| Sales | 8,636,000 | 8,909,200 | 8,066,000 |
| Maturities, calls and redemptions | 1,418,600 | 1,313,600 | 1,318,700 |
| Purchases of equity securities | (1,476,300) | (1,561,400) | (912,000) |
| Proceeds from sales of equity securities | 1,592,800 | 1,471,100 | 746,500 |
| Purchases of other invested assets | (433,100) | (505,800) | (205,700) |
| Proceeds from sales of other invested assets | 304,900 | 85,900 | 124,700 |
| Changes in collateral and settlement of non-hedging derivatives | (34,500) | (36,500) | (67,400) |
| Changes in securities lending collateral | 222,000 | 214,400 | (545,600) |
| Purchases of subsidiaries, net of cash acquired | 0 | (638,900) | 0 |
| Proceeds from sale of subsidiary, net of cash sold | 0 | 0 | 740,000 |
| Purchases of property and equipment | (583,600) | (638,200) | (714,600) |
| Proceeds from sales of property and equipment | 0 | 35,300 | 88,000 |
| Other, net | (3,000) | (8,200) | (100) |
| Net cash used in investing activities | (513,900) | (1,151,500) | (974,900) |
| Financing activities | |||
| Net (repayments of) proceeds from commercial paper borrowings | (53,200) | 682,200 | (379,200) |
| Proceeds from long-term borrowings | 0 | 1,226,500 | 2,700,000 |
| Repayments of long-term borrowings | 0 | (2,697,200) | (1,730,100) |
| Proceeds from short-term borrowings | 2,400,000 | 2,760,000 | 2,050,000 |
| Repayments of short-term borrowings | (2,500,000) | (2,620,000) | (2,050,000) |
| Changes in securities lending payable | (222,000) | (214,400) | 545,600 |
| Changes in bank overdrafts | 513,800 | (243,800) | 173,000 |
| Premiums paid on equity call options | 0 | (16,700) | 0 |
| Proceeds from sale of put options | 0 | 16,600 | 0 |
| Repurchase and retirement of common stock | 0 | (1,515,800) | (2,998,800) |
| Change in collateral and settlements of debt-related derivatives | (360,400) | 0 | 0 |
| Cash dividends | (684,000) | (656,600) | (480,700) |
| Proceeds from issuance of common stock under employee stock plans | 119,400 | 186,000 | 301,300 |
| Excess tax benefits from share-based compensation | 53,500 | 95,800 | 46,400 |
| Net cash used in financing activities | (732,900) | (2,997,400) | (1,822,500) |
| Effect of foreign exchange rates on cash and cash equivalents | 4,100 | (5,300) | (7,100) |
| Change in cash and cash equivalents | 1,961,800 | (38,200) | 564,800 |
| Cash and cash equivalents at beginning of year | 2,113,500 | 2,151,700 | |
| Cash and cash equivalents at end of year | 4,075,300 | 2,113,500 | 2,151,700 |
| External Links | |
| ELEVANCE HEALTH, INC. (ELV) Fiscal Year 2016 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |